Merck hit with Phase III failure for Parkinson's drug

Merck & Co is discontinuing development of its adenosine A2a receptor antagonist, preladenant, for Parkinson's disease (PD) after an initial review of data from three separate Phase III trials failed to provide evidence of efficacy for the drug versus placebo.